AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Etokimab
ANB030
ANB032
Partnerships
Clinical Trials
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
August 10, 2020
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
August 10, 2020
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
About
Technology
Pipeline
Investors
Careers
